Last reviewed · How we verify
LBS-007
At a glance
| Generic name | LBS-007 |
|---|---|
| Sponsor | Lin BioScience, Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LBS-007 CI brief — competitive landscape report
- LBS-007 updates RSS · CI watch RSS
- Lin BioScience, Inc portfolio CI